A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continued Access Period.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ulcerative Colitis
- Ulcerative Colitis Chronic
- Inflammatory Bowel Diseases
- Crohn's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 2 to 19 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UCSF Medical Center at Mission Bay · San Francisco, CA
Connecticut · 1
- Connecticut Children's Medical Center · Hartford, CT
Georgia · 2
- Children's Center for Digestive Health Care, LLC · Atlanta, GA
- Emory University School of Medicine · Atlanta, GA
Massachusetts · 2
- Boston Children's Hospital · Boston, MA
- Massachusetts General Hospital · Waltham, MA
Missouri · 1
- Washington University School of Medicine · St Louis, MO
New York · 1
- Icahn School of Medicine at Mount Sinai · New York, NY
Texas · 1
- Cook Children's Medical Center · Fort Worth, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.